Carol Moore: Daily

Tekton Research launches its first multi-specialty clinical trial hub in San Antonio, leveraging top physician expertise to tackle diabetes and obesity.

A new auction house built for Black artists uses proprietary AI to fight historical undervaluation. Can its data-driven model truly create equity?

Apollo's new Go Stellar scooter packs 32 MPH speeds and self-healing tires, targeting a key urban niche. But can it navigate a complex regulatory landscape?

centralwOrld's 2026 Songkran blends ancient arts with a giant water slide and T-Pop stars, a bold play for Thailand's cultural and economic future.

Orange County residents can get free, certified compost on April 18, turning green waste into a powerful tool for fighting climate change in their own backyards.

North American Construction Group finalizes its acquisition of Iron Mine Contracting, a strategic move into Australia's booming rare earth sector.

A new bispecific antibody aims to treat the 50% of AxSpA patients who find no relief, as Fortitude Biomedicines enters a competitive autoimmune market.

After a decade under corporate ownership, Gary Heck reacquires Kenwood Vineyards for a fraction of its 2014 sale price, a bold bet on Sonoma heritage.

Upsher-Smith launches its first prescription ear drop, a generic of Ciprodex®, entering a $118M market and promising a more affordable option for patients.

Brokerage firm JWTT Inc. deepens its niche focus, hiring veteran Mike Acampora and opening a Jacksonville office to dominate the community bank advisory market.

A new white paper details how the BioShare platform helps research institutions navigate the NIH's complex and costly new cybersecurity requirements.

A key predictive index for employment declined in March, suggesting the resilient U.S. labor market may be cooling amid rising uncertainty and employer hesitancy.

Fintech firm Pagaya's latest AAA-rated deal attracts new investors, signaling strong confidence in its AI-driven lending model despite economic headwinds.

With new CEO Stan Lequin and private equity backing, Fidus Systems is pivoting to infuse AI into embedded design, signaling a new era of growth and M&A.

Apnimed has secured up to $150M to launch AD109, a potential first-ever pill for sleep apnea, promising relief for millions tired of CPAP machines.

A new service brings quiet, eco-friendly robotic lawnmowers to Toronto and Hamilton, promising to save homeowners time, money, and weekend headaches.

Starbucks cedes majority control in China to Boyu Capital in a bold pivot, aiming for 20,000 stores amid fierce competition from local rivals.

A $10M investment from BVF Partners propels Entera Bio’s revolutionary oral osteoporosis drug into a pivotal Phase 3 trial, a major step for patients.

Two leading nonprofits, backed by Salesforce, are tackling the chaotic rise of AI in classrooms, aiming to build an ethical and effective model for all.

Cheer Holding enacts a 1-for-3 reverse stock split to avoid delisting. But with a history of similar moves, what does this mean for investors?